Net profit of Unichem Laboratories rose 341.78% to Rs 9.94 crore in the quarter ended March 2019 as against Rs 2.25 crore during the previous quarter ended March 2018. Sales rose 36.20% to Rs 277.08 crore in the quarter ended March 2019 as against Rs 203.44 crore during the previous quarter ended March 2018.

For the full year,net profit declined 99.66% to Rs 8.80 crore in the year ended March 2019 as against Rs 2556.60 crore during the previous year ended March 2018. Sales rose 45.29% to Rs 967.74 crore in the year ended March 2019 as against Rs 666.08 crore during the previous year ended March 2018.

Powered by Capital Market - Live News

Unichem Laboratories Limited announced that it received tentative ANDA approval from USFDA for Unichem's Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets USP, 5 mg/120 mg (OTC) to market a generic version of Johnson and Johnson Consumer Inc's Zyrtec-D 12 Hour (Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride, 5mg/120 mg) Extended Tablets. These are indicated for antihistamine and nasal decongestant. The Product will be commercialized from Unichemls Goa Plant on receipt of final approval.

Powered by Capital Market - Live News

Unichem Laboratories Limited announced that it received tentative ANDA approval from USFDA for Unichem's Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets USP, 5 mg/120 mg (OTC) to market a generic version of Johnson and Johnson Consumer Inc's Zyrtec-D 12 Hour (Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride, 5mg/120 mg) Extended Tablets. These are indicated for antihistamine and nasal decongestant. The Product will be commercialized from UnichemlsGoaPlant on receipt of final approval.

Powered by Capital Market - Live News

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 24 May 2019.

Powered by Capital Market - Live News